• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估在中国推出疫苗的同时,COVID-19 负担向年轻人群转移的情况。

Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.

机构信息

School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People's Republic of China.

Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, People's Republic of China.

出版信息

Emerg Microbes Infect. 2022 Dec;11(1):1205-1214. doi: 10.1080/22221751.2022.2063073.

DOI:10.1080/22221751.2022.2063073
PMID:35380100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9045766/
Abstract

SARS-CoV-2 infection causes most cases of severe illness and fatality in older age groups. Over 92% of the Chinese population aged ≥12 years has been fully vaccinated against COVID-19 (albeit with vaccines developed against historical lineages). At the end of October 2021, the vaccination programme has been extended to children aged 3-11 years. Here, we aim to assess whether, in this vaccination landscape, the importation of Delta variant infections could shift COVID-19 burden from adults to children. We developed an age-structured susceptible-infectious-removed model of SARS-CoV-2 transmission to simulate epidemics triggered by the importation of Delta variant infections and project the age-specific incidence of SARS-CoV-2 infections, cases, hospitalizations, intensive care unit admissions, and deaths. In the context of the vaccination programme targeting individuals aged ≥12 years, and in the absence of non-pharmaceutical interventions, the importation of Delta variant infections could have led to widespread transmission and substantial disease burden in mainland China, even with vaccination coverage as high as 89% across the eligible age groups. Extending the vaccination roll-out to include children aged 3-11 years (as it was the case since the end of October 2021) is estimated to dramatically decrease the burden of symptomatic infections and hospitalizations within this age group (39% and 68%, respectively, when considering a vaccination coverage of 87%), but would have a low impact on protecting infants. Our findings highlight the importance of including children among the target population and the need to strengthen vaccination efforts by increasing vaccine effectiveness.

摘要

SARS-CoV-2 感染导致年龄较大的人群中大多数严重疾病和死亡。超过 92%的中国≥12 岁人群已完全接种了 COVID-19 疫苗(尽管是针对历史谱系开发的疫苗)。2021 年 10 月底,疫苗接种计划已扩大到 3-11 岁儿童。在这里,我们旨在评估在这种疫苗接种背景下,Delta 变异株感染的输入是否会将 COVID-19 负担从成年人转移到儿童身上。我们开发了一个基于年龄结构的 SARS-CoV-2 传播易感性感染消除模型,以模拟由 Delta 变异株感染输入引发的流行,并预测 SARS-CoV-2 感染、病例、住院、重症监护病房入院和死亡的特定年龄发病率。在针对≥12 岁人群的疫苗接种计划背景下,并且在没有非药物干预的情况下,Delta 变异株感染的输入可能导致中国大陆广泛传播和大量疾病负担,即使在合格年龄组中接种率高达 89%。扩大疫苗接种范围以包括 3-11 岁儿童(自 2021 年 10 月底以来一直如此)预计将显著降低该年龄组中症状感染和住院的负担(分别为 39%和 68%,当考虑 87%的疫苗接种覆盖率时),但对保护婴儿的影响很小。我们的研究结果强调了将儿童纳入目标人群的重要性,以及需要通过提高疫苗效力来加强疫苗接种工作的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/70f7f3ebe4a4/TEMI_A_2063073_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/eca3a22a9b8f/TEMI_A_2063073_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/e6f66ce9e262/TEMI_A_2063073_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/70f7f3ebe4a4/TEMI_A_2063073_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/eca3a22a9b8f/TEMI_A_2063073_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/e6f66ce9e262/TEMI_A_2063073_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917a/9045766/70f7f3ebe4a4/TEMI_A_2063073_F0003_OC.jpg

相似文献

1
Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China.评估在中国推出疫苗的同时,COVID-19 负担向年轻人群转移的情况。
Emerg Microbes Infect. 2022 Dec;11(1):1205-1214. doi: 10.1080/22221751.2022.2063073.
2
[Technical guidelines for seasonal influenza vaccination in China (2021-2022)].《中国季节性流感疫苗接种技术指南(2021—2022年)》
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1722-1749. doi: 10.3760/cma.j.cn112338-20210913-00732.
3
Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.通过非药物干预和为儿童接种疫苗来减轻澳大利亚的 SARS-CoV-2 Delta 疾病负担:建模分析。
BMC Med. 2022 Feb 18;20(1):80. doi: 10.1186/s12916-022-02241-3.
4
[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].《中国季节性流感疫苗接种技术指南(2020—2021年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Oct 6;54(10):1035-1059. doi: 10.3760/cma.j.cn112150-20200911-01198.
5
Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.美国 2020 年 12 月至 2021 年 9 月,疫苗接种者预防 COVID-19 感染、住院和死亡人数的估计数。
JAMA Netw Open. 2022 Jul 1;5(7):e2220385. doi: 10.1001/jamanetworkopen.2022.20385.
6
Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.非药物干预措施、疫苗接种和 SARS-CoV-2 德尔塔变异株在英国:一项数学建模研究。
Lancet. 2021 Nov 13;398(10313):1825-1835. doi: 10.1016/S0140-6736(21)02276-5. Epub 2021 Oct 28.
7
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.2021 年 5 月 1 日至 7 月 25 日,加利福尼亚州洛杉矶县≥16 岁人群中,根据疫苗接种状况划分的 SARS-CoV-2 感染和住院情况。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
8
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.中国广东奥密克戎 BA.2 感染突破性感染用灭活 COVID-19 疫苗加强接种的效果:一项队列研究。
Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023.
9
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.腺病毒 5 型载体疫苗和灭活 COVID-19 疫苗对由 B.1.617.2(德尔塔)变异株引起的有症状 COVID-19、COVID-19 肺炎和重症 COVID-19 的有效性:来自中国云南 2021 年暴发疫情的证据。
Vaccine. 2022 May 3;40(20):2869-2874. doi: 10.1016/j.vaccine.2022.03.067. Epub 2022 Apr 1.
10
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南(2022—2023年)》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.

引用本文的文献

1
Assessing the impact of interventions on the major Omicron BA.2 outbreak in spring 2022 in Shanghai.评估干预措施对2022年春季上海主要奥密克戎BA.2疫情的影响。
Infect Dis Model. 2024 Feb 28;9(2):519-526. doi: 10.1016/j.idm.2024.02.013. eCollection 2024 Jun.
2
Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.预测 SARS-CoV-2 导致的健康结果的模型,包括疫苗接种的效果:系统评价。
Syst Rev. 2024 Jan 16;13(1):30. doi: 10.1186/s13643-023-02411-1.
3
Relationship of close contact settings with transmission and infection during the SARS-CoV-2 Omicron BA.2 epidemic in Shanghai.

本文引用的文献

1
Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.全球 COVID-19 疫苗政策、覆盖范围和需求的多样性:描述性研究。
BMC Med. 2022 Apr 4;20(1):130. doi: 10.1186/s12916-022-02333-0.
2
Unvaccinated Children Are an Important Link in the Transmission of SARS-CoV-2 Delta Variant (B1.617.2): Comparative Clinical Evidence From a Recent Community Surge.未接种疫苗的儿童是 SARS-CoV-2 德尔塔变异株(B1.617.2)传播的重要环节:近期社区疫情中的比较临床证据。
Front Cell Infect Microbiol. 2022 Mar 8;12:814782. doi: 10.3389/fcimb.2022.814782. eCollection 2022.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
密切接触设置与上海 SARS-CoV-2 奥密克戎 BA.2 流行期间传播和感染的关系。
BMJ Glob Health. 2023 Dec 22;8(12):e012289. doi: 10.1136/bmjgh-2023-012289.
4
Impact of vaccination and non-pharmacological interventions on COVID-19: a review of simulation modeling studies in Asia.疫苗接种和非药物干预对 COVID-19 的影响:亚洲模拟建模研究综述。
Front Public Health. 2023 Sep 25;11:1252719. doi: 10.3389/fpubh.2023.1252719. eCollection 2023.
5
Age-specific transmission dynamics under suppression control measures during SARS-CoV-2 Omicron BA.2 epidemic.奥密克戎 BA.2 流行期间抑制控制措施下的特定年龄传播动力学。
BMC Public Health. 2023 Apr 22;23(1):743. doi: 10.1186/s12889-023-15596-w.
比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021.2021年中国新冠病毒灭活疫苗对德尔塔变异株所致有症状感染、肺炎及重症疾病的有效性:真实世界研究与证据
China CDC Wkly. 2022 Jan 28;4(4):57-65. doi: 10.46234/ccdcw2022.009.
5
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis.阿尔法和德尔塔 SARS-CoV-2 变异株的生成时间:一项流行病学分析。
Lancet Infect Dis. 2022 May;22(5):603-610. doi: 10.1016/S1473-3099(22)00001-9. Epub 2022 Feb 14.
6
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.巴西异源科兴加辉瑞疫苗有效性。
Nat Med. 2022 Apr;28(4):838-843. doi: 10.1038/s41591-022-01701-w. Epub 2022 Feb 9.
7
Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.在中国广东省疫情期间,灭活 COVID-19 疫苗对 B.1.617.2(德尔塔)变异株引起的疾病的有效性:一项队列研究。
Ann Intern Med. 2022 Apr;175(4):533-540. doi: 10.7326/M21-3509. Epub 2022 Feb 1.
8
Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China.研究疫苗诱导的免疫及其在中国减轻 SARS-CoV-2 流行中的作用。
BMC Med. 2022 Jan 31;20(1):37. doi: 10.1186/s12916-022-02243-1.
9
Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France.部分接种人群中 SARS-CoV-2 流行的流行病学和控制:应用于法国的建模研究。
BMC Med. 2022 Jan 26;20(1):33. doi: 10.1186/s12916-022-02235-1.
10
Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China.中国江苏 B.1.617.2(Delta)变异株感染者中新冠灭活疫苗对重症的保护效果。
Int J Infect Dis. 2022 Mar;116:204-209. doi: 10.1016/j.ijid.2022.01.030. Epub 2022 Jan 19.